Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh D. Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini

Blood blood.2022019406.

https://doi.org/10.1182/blood.2022019406

Published: 2023

Includes: Supplemental data

Journal Articles

Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers

Blood (2022) 140 (Supplement 1): 4839–4842.

https://doi.org/10.1182/blood-2022-164619

Published: 2022

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios-Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C. Minnema, Ashutosh D. Wechalekar, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Stefan Schönland

Blood (2022) 140 (Supplement 1): 7294–7296.

https://doi.org/10.1182/blood-2022-169688

Published: 2022

Journal Articles

International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation

Blood (2022) 140 (Supplement 1): 5225–5227.

https://doi.org/10.1182/blood-2022-165010

Published: 2022

Journal Articles

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Blood (2022) 140 (Supplement 1): 10434–10436.

https://doi.org/10.1182/blood-2022-169736

Published: 2022

Journal Articles

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Blood (2021) 138 (Supplement 1): 153.

https://doi.org/10.1182/blood-2021-152675

Published: 2021

Journal Articles

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Blood (2021) 138 (Supplement 1): 485.

https://doi.org/10.1182/blood-2021-152391

Published: 2021

Journal Articles

Two-Year Evaluation of the German Clinical Amyloidosis Registry

Ute Hegenbart, Niklas Fuhr, Laura Huber, Christoph Kimmich, Kaya Veelken, Tobias Dittrich, Rita Ziehl, Fabian aus dem Siepen, Alexander Carpinteiro, Timon Hansen, Carsten Müller-Tidow, Axel Benner, Stefan Schönland

Blood (2021) 138 (Supplement 1): 3780.

https://doi.org/10.1182/blood-2021-152713

Published: 2021

Journal Articles

Multi-Modality Imaging Reveals Structural Centrosome Aberrations As a Potential Driver of Chromosomal Instability in Early-Stage Plasma Cell Disorders

Sebastian Köhrer, Tobias Dittrich, Martin Schorb, Niels Weinhold, Isabella Haberbosch, Mandy Börmel, Gabor Pajor, Hartmut Goldschmidt, Carsten Müller-Tidow, Marc-Steffen Raab, Alexander Brobeil, Peter Dreger, Ute Hegenbart, Stefan Schönland, Yannick Schwab, Alwin Krämer

Blood (2021) 138 (Supplement 1): 1579.

https://doi.org/10.1182/blood-2021-150747

Published: 2021

Journal Articles

Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission

Blood (2021) 138 (Supplement 1): 1783.

https://doi.org/10.1182/blood-2021-145100

Published: 2021

Journal Articles

Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation

Felix Korell, Nicholas Schreck, Axel Benner, Tobias Liebregts, Stefan Schönland, Ute Hegenbart, Aleksandar Radujkovic, Michael Schmitt, Peter Dreger, Thomas Luft

Blood (2021) 138 (Supplement 1): 1774.

https://doi.org/10.1182/blood-2021-153104

Published: 2021

Journal Articles

Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)

Yuntian Ding, Lei Wang, Ming Ni, Wenjie Gong, Sanmei Wang, Brigitte Neuber, Maria-Luisa Schubert, Tim Sauer, Angela Hückelhoven-Krauss, Thomas Luft, Ute Hegenbart, Stefan Schönland, Volker Eckstein, Jishi Wang, William Hermann Krüger, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt

Blood (2021) 138 (Supplement 1): 1810.

https://doi.org/10.1182/blood-2021-150106

Published: 2021

Journal Articles

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Blood (2021) 138 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2021-149594

Published: 2021

Journal Articles

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Blood (2021) 138 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2021-149222

Published: 2021

Journal Articles

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Blood (2021) 138 (Supplement 1): 159.

https://doi.org/10.1182/blood-2021-146820

Published: 2021

Journal Articles

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Vaishali Sanchorawala, Ashutosh D. Wechalekar, Kihyun Kim, Stefan Schönland, Heather J Landau, Kwok Fiona, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond Comenzo, Dasha Cherepanov, Vanessa C Hayden, Arun Kumar, Richard Labotka, Douglas V. Faller, Efstathios Kastritis

Blood (2021) 138 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2021-148689

Published: 2021

Journal Articles

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Giovanni Palladini, MD PhD, Stefan Schönland, MD, Giampaolo Merlini, MD, Paolo Milani, MDPhD, Arnaud Jaccard, MD PhD, Frank Bridoux, MD PhD, Wilfried Roeloffzen, MD PhD, M. Teresa Cibeira, MD PhD, Hermine Agis, MD, Monique C. Minnema, MD PhD, Rui Bergantim, MD, Roman Hajek, MD PhD, Cristina João, MD PhD MSc, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM, Pieter Sonneveld, MD PhD, Efstathios Kastritis, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140708

Published: 2020

Journal Articles

Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone

Marco Basset, MD, Christoph Kimmich, Tobias Dittrich, MD, Kaya Veelken, MD, Hartmut Goldschmidt, MD, Dirk Hose, MD, Anja Seckinger, MD, Anna Jauch, Carsten Mueller-Tidow, MD, Ute Hegenbart, MD, Stefan Schönland, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142701

Published: 2020

Journal Articles

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey

Paolo Milani, MDPhD, Vaishali Sanchorawala, MD, Ramon Lecumberri, MD PhD, Sunil Saith, MD, Mathew S. Maurer, MD, M. Teresa Cibeira, MD PhD, Giampaolo Merlini, MD, Stefan Schönland, MD, Giovanni Palladini, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-141569

Published: 2020

Journal Articles

Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients

Paolo Milani, MDPhD, Nelson Leung, MD, Efstathios Kastritis, MD, Stefan Schönland, MD, Ute Hegenbart, MD, Frank Bridoux, MD, Florent Joly, MD, Sascha A Tuchman, MD, Victor Jimenez-Zepeda, MD, Sriram Ravichandran, MBBS, MRCP, FRCPath, Holly Lee, MD, Tamara Berno, MD, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141662

Published: 2020

NARROW

Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Two-Year Evaluation of the German Clinical Amyloidosis Registry

Multi-Modality Imaging Reveals Structural Centrosome Aberrations As a Potential Driver of Chromosomal Instability in Early-Stage Plasma Cell Disorders

Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission

Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation

Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey

Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only